BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 11929321)

  • 1. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.
    Song JC; White CM
    Clin Pharmacokinet; 2002; 41(3):207-24. PubMed ID: 11929321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin converting enzyme inhibitors and moderate hypertension.
    McAreavey D; Robertson JI
    Drugs; 1990 Sep; 40(3):326-45. PubMed ID: 2226219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists.
    Zannad F; Matzinger A; Larché J
    Am J Hypertens; 1996 Jul; 9(7):633-43. PubMed ID: 8806975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.
    Hoyer J; Schulte KL; Lenz T
    Clin Pharmacokinet; 1993 Mar; 24(3):230-54. PubMed ID: 8462229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of the angiotensin-converting-enzyme inhibitors.
    Piepho RW
    Am J Health Syst Pharm; 2000 Oct; 57 Suppl 1():S3-7. PubMed ID: 11030016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer ACE inhibitors. A look at the future.
    Salvetti A
    Drugs; 1990 Dec; 40(6):800-28. PubMed ID: 2078997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor.
    Hosoya K; Ishimitsu T
    Cardiovasc Drug Rev; 2002; 20(2):93-110. PubMed ID: 12177688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors.
    White CM
    Pharmacotherapy; 1998; 18(3):588-99. PubMed ID: 9620109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
    Cushman DW; Wang FL; Fung WC; Grover GJ; Harvey CM; Scalese RJ; Mitch SL; DeForrest JM
    Br J Clin Pharmacol; 1989; 28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. PubMed ID: 2557876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug interactions with ACE inhibitors.
    Breckenridge AM
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():133-8. PubMed ID: 2674438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative evaluation of ACE inhibitors: which differences are relevant?].
    Fischler MP; Follath F
    Schweiz Med Wochenschr; 1999 Jul; 129(29-30):1053-60. PubMed ID: 10464907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited.
    Knütter I; Wollesky C; Kottra G; Hahn MG; Fischer W; Zebisch K; Neubert RH; Daniel H; Brandsch M
    J Pharmacol Exp Ther; 2008 Nov; 327(2):432-41. PubMed ID: 18713951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and determination of antihypertonics from the group of angiotensin-convertase inhibitors by densitometric method in comparition with HPLC method.
    Wyszomirska E; Czerwińska K; Mazurek AP
    Acta Pol Pharm; 2010; 67(2):137-43. PubMed ID: 20369790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients.
    Langtry HD; Markham A
    Drugs Aging; 1997 Feb; 10(2):131-66. PubMed ID: 9061270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trandolapril: a newer angiotensin-converting enzyme inhibitor.
    Guay DR
    Clin Ther; 2003 Mar; 25(3):713-75. PubMed ID: 12852701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico and in vitro screening for carcinogenic potential of angiotensin-converting enzyme inhibitors and their degradation impurities.
    Regulska K; Matera-Witkiewicz A; Mikołajczyk A; Stanisz BJ
    Toxicol Appl Pharmacol; 2023 Jun; 469():116541. PubMed ID: 37149094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of the newer ACE inhibitors. A review.
    Kelly JG; O'Malley K
    Clin Pharmacokinet; 1990 Sep; 19(3):177-96. PubMed ID: 2203579
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.